ACC announces late-breaking clinical trial lineup for 2024 Scientific Session

ByScott Buzby

Fact checked byRichard Smith

Key takeaways:

The ACC announced the late-breaking clinical trial lineup for its 2024 Scientific Session.
The meeting will feature five late-breaking science sessions across the 3-day meeting.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held April 6-8 in Atlanta and online.

The lineup is as follows:

Late-Breaking Clinical Trials I: Joint ACC/Journal of the American College of Cardiology Late-Breaking Clinical Trials

the double-blind, randomized placebo controlled RELIEVE-HF trial of an interatrial shunt in patients with HF with reduced and preserved ejection fraction;
the EMPACT-MI trial of empagliflozin (Jardiance, Boehringer Ingelheim) after acute MI; and
the AEGIS-II trial evaluating CV outcomes following apolipoprotein A-I infusions in patients with acute MI.

Late-Breaking Clinical Trials II

the BE ACTIVE randomized clinical trial of gamification, financial incentives or both combined to increase physical activity among patients with increased risk for major adverse CV events;
the phase 2 KARDIA-2 study of zilebesiran (Alnylam), a novel RNA interference agent, plus standard care in patients with inadequately controlled hypertension;
the BRIDGE CS8-TIMI 73a trial evaluating the safety and efficacy of olezarsen (Ionis), an investigational ligand-conjugated antisense drug, in patients with hypertriglyceridemia and elevated CV risk;
a randomized-controlled, double-blind, phase 3 study to evaluate the long-term efficacy and safety of lerodalcibep (LIB003, LIB Therapeutics) in patients at high CV risk on stable lipid-lowering therapy; and
the final results of the SHASTA-2 trial of plozasiran, formerly ARO-APOC3 (Arrowhead Pharmaceuticals), for the reduction of apolipoprotein C-III and triglycerides in patients with severe hypertriglyceridemia.

Late-Breaking Clinical Trials III: Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials

the randomized SMART trial: self-expanding compared with balloon-expandable transcatheter aortic valve replacement in patients with small aortic annuli;
the TACT2 trial of edetate disodium-based chelation infusions after MI in patients with diabetes;
the REDUCE-AMI trial to assess long-term beta-blocker treatment after acute MI in patients with preserved left ventricular EF:
the DanGer Shock trial of a percutaneous transvalvular microaxial flow pump in patients with infarct-related cardiogenic shock; and
the results of the double-blind, placebo-controlled ULTIMATE-DAPT trial of 1-month ticagrelor monotherapy after PCI in patients with ACS.

Late-Breaking Clinical Trials IV: Joint ACC/Journal of the American Medical Association Late-Breaking Clinical Trials

the phase 3 randomized-controlled ARISE-HF study of a selective aldose reductase inhibitor for the treatment of diabetic cardiomyopathy;
the results of the IMPROVE-HCM trial evaluating the safety and efficacy of ninerafaxstat (Imbria Pharmaceuticals), a novel cardiac mitotrope, for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy;
a trial evaluating topical tranexamic acid for the prevention of seizures in cardiac surgery;
the PROACT trial of enalapril for the prevention of cardiac damage in patients treated for breast cancer and lymphoma; and
the TACTiC trial of technology-assisted nonprescription rosuvastatin administration.

Late-Breaking Clinical Trials V

the ORBITA-COSMIC trial of a coronary sinus reducer for the treatment of refractory angina;
the 1-year outcomes of the randomized DEDICATE-DZHK6 trial that evaluated TAVR compared with surgical AVR in patients at low to intermediate risk;
the 3-month results of the TARGET BP I randomized trial of to assess the effect of alcohol-mediated renal denervation on BP in the presence of antihypertensive therapy;
a trial evaluating preventive PCI compared with medical therapy atherosclerotic coronary vulnerable plaques; and
a comparison of IVUS-guided compared with angiography-guided angioplasty for the treatment of femoropopliteal artery disease with a drug-coated balloon.

In addition to the five late-breaking science sessions, the meeting will feature two “deep dive” sessions to provide attendees additional insight on key trials as well as three featured clinical research sessions.

Healio will be on-site in Atlanta to report the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and more. Follow our breaking updates here and via @CardiologyToday on X (formerly Twitter).

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

American College of Cardiology

Read more